JP2019533684A - リポソームイリノテカン、オキサリプラチン、５−フルオロウラシル（およびロイコボリン）を含む併用療法を用いる胃がんの処置 - Google Patents

リポソームイリノテカン、オキサリプラチン、５−フルオロウラシル（およびロイコボリン）を含む併用療法を用いる胃がんの処置 Download PDF

Info

Publication number
JP2019533684A
JP2019533684A JP2019522381A JP2019522381A JP2019533684A JP 2019533684 A JP2019533684 A JP 2019533684A JP 2019522381 A JP2019522381 A JP 2019522381A JP 2019522381 A JP2019522381 A JP 2019522381A JP 2019533684 A JP2019533684 A JP 2019533684A
Authority
JP
Japan
Prior art keywords
oxaliplatin
leucovorin
irinotecan
administered
fluorouracil
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
JP2019522381A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019533684A5 (cg-RX-API-DMAC7.html
Inventor
ビン ジャン，
ビン ジャン，
シュテファン ブラウン，
シュテファン ブラウン，
ジョナサン バジル フィッツジェラルド，
ジョナサン バジル フィッツジェラルド，
アシシュ カルラ，
アシシュ カルラ，
シャノン レオナルド，
シャノン レオナルド，
Original Assignee
イプセン バイオファーム リミティド
イプセン バイオファーム リミティド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by イプセン バイオファーム リミティド, イプセン バイオファーム リミティド filed Critical イプセン バイオファーム リミティド
Publication of JP2019533684A publication Critical patent/JP2019533684A/ja
Publication of JP2019533684A5 publication Critical patent/JP2019533684A5/ja
Priority to JP2022146925A priority Critical patent/JP2022171808A/ja
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4453—Non condensed piperidines, e.g. piperocaine only substituted in position 1, e.g. propipocaine, diperodon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/243—Platinum; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Dispersion Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Dermatology (AREA)
  • Inorganic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
JP2019522381A 2016-11-02 2017-11-01 リポソームイリノテカン、オキサリプラチン、５−フルオロウラシル（およびロイコボリン）を含む併用療法を用いる胃がんの処置 Ceased JP2019533684A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2022146925A JP2022171808A (ja) 2016-11-02 2022-09-15 リポソームイリノテカン、オキサリプラチン、５－フルオロウラシル（およびロイコボリン）を含む併用療法を用いる胃がんの処置

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662416317P 2016-11-02 2016-11-02
US62/416,317 2016-11-02
PCT/GB2017/053293 WO2018083470A1 (en) 2016-11-02 2017-11-01 Treating gastric cancer using combination therapies comprising liposomal irinotecan, oxaliplatin, 5-fluoruracil (and leucovorin)

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2022146925A Division JP2022171808A (ja) 2016-11-02 2022-09-15 リポソームイリノテカン、オキサリプラチン、５－フルオロウラシル（およびロイコボリン）を含む併用療法を用いる胃がんの処置

Publications (2)

Publication Number Publication Date
JP2019533684A true JP2019533684A (ja) 2019-11-21
JP2019533684A5 JP2019533684A5 (cg-RX-API-DMAC7.html) 2020-12-10

Family

ID=60569939

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2019522381A Ceased JP2019533684A (ja) 2016-11-02 2017-11-01 リポソームイリノテカン、オキサリプラチン、５−フルオロウラシル（およびロイコボリン）を含む併用療法を用いる胃がんの処置
JP2022146925A Pending JP2022171808A (ja) 2016-11-02 2022-09-15 リポソームイリノテカン、オキサリプラチン、５－フルオロウラシル（およびロイコボリン）を含む併用療法を用いる胃がんの処置

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2022146925A Pending JP2022171808A (ja) 2016-11-02 2022-09-15 リポソームイリノテカン、オキサリプラチン、５－フルオロウラシル（およびロイコボリン）を含む併用療法を用いる胃がんの処置

Country Status (18)

Country Link
US (1) US11071726B2 (cg-RX-API-DMAC7.html)
EP (1) EP3535026A1 (cg-RX-API-DMAC7.html)
JP (2) JP2019533684A (cg-RX-API-DMAC7.html)
KR (1) KR20190077441A (cg-RX-API-DMAC7.html)
CN (1) CN110402163A (cg-RX-API-DMAC7.html)
AU (1) AU2017354903B2 (cg-RX-API-DMAC7.html)
BR (1) BR112019007844A2 (cg-RX-API-DMAC7.html)
CA (1) CA3040395A1 (cg-RX-API-DMAC7.html)
EA (1) EA201990979A1 (cg-RX-API-DMAC7.html)
IL (2) IL266187A (cg-RX-API-DMAC7.html)
MA (1) MA46709A (cg-RX-API-DMAC7.html)
MX (1) MX392408B (cg-RX-API-DMAC7.html)
MY (1) MY202377A (cg-RX-API-DMAC7.html)
PH (1) PH12019500892A1 (cg-RX-API-DMAC7.html)
RU (1) RU2761953C2 (cg-RX-API-DMAC7.html)
SG (2) SG11201903615WA (cg-RX-API-DMAC7.html)
TW (1) TWI791467B (cg-RX-API-DMAC7.html)
WO (1) WO2018083470A1 (cg-RX-API-DMAC7.html)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4218730B1 (en) * 2004-05-03 2023-11-01 Ipsen Biopharm Ltd. Liposomes useful for drug delivery
AU2013202947B2 (en) 2012-06-13 2016-06-02 Ipsen Biopharm Ltd. Methods for treating pancreatic cancer using combination therapies comprising liposomal irinotecan
US9717724B2 (en) 2012-06-13 2017-08-01 Ipsen Biopharm Ltd. Methods for treating pancreatic cancer using combination therapies
US11318131B2 (en) 2015-05-18 2022-05-03 Ipsen Biopharm Ltd. Nanoliposomal irinotecan for use in treating small cell lung cancer
SG10201913073YA (en) 2015-08-20 2020-03-30 Ipsen Biopharm Ltd Combination therapy using liposomal irinotecan and a parp inhibitor for cancer treatment
US20170049775A1 (en) 2015-08-21 2017-02-23 Merrimack Pharmaceuticals, Inc. Methods for Treating Metastatic Pancreatic Cancer Using Combination Therapies Comprising Liposomal Irinotecan and Oxaliplatin
CN114099437A (zh) 2015-10-16 2022-03-01 易普森生物制药有限公司 稳定喜树碱药物组合物
RU2761953C2 (ru) 2016-11-02 2021-12-14 Ипсен Биофарм Лтд. Лечение рака желудка с применением комбинационных видов терапии, содержащих липосомальный иринотекан, оксалиплатин, 5-фторурацил (и лейковорин)
JP6728482B2 (ja) 2017-03-31 2020-07-22 富士フイルム株式会社 リポソーム組成物および医薬組成物
PL3811931T3 (pl) 2018-06-20 2024-11-18 Fujifilm Corporation Skojarzony środek leczniczy zawierający kompozycję liposomową z kapsułkowanym lekiem i inhibitor punktu kontroli immunologicznej
CN112789032A (zh) * 2018-10-01 2021-05-11 富士胶片株式会社 包含内含药物的脂质体组合物及铂制剂的组合医药
CN113164600A (zh) * 2018-10-17 2021-07-23 百欧林纳克斯有限公司 转移性胰脏腺癌的治疗
US20220072087A1 (en) * 2019-01-17 2022-03-10 Biolinerx Ltd. Specific combination therapy for treatment of pancreatic cancer
WO2020148744A1 (en) * 2019-01-17 2020-07-23 Biolinerx Ltd. Combination therapy for treatment of pancreatic cancer
EP3988086A1 (en) * 2019-02-22 2022-04-27 Novocure GmbH Treating gastric cancer using ttfields and drug in combination

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2015523355A (ja) * 2012-06-13 2015-08-13 メリマック ファーマシューティカルズ インコーポレーティッド リポソームイリノテカンを含む併用療法を用いた、膵臓癌を治療するための方法

Family Cites Families (85)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6019790A (ja) 1983-07-14 1985-01-31 Yakult Honsha Co Ltd 新規なカンプトテシン誘導体
US5077056A (en) 1984-08-08 1991-12-31 The Liposome Company, Inc. Encapsulation of antineoplastic agents in liposomes
JPH0720857B2 (ja) 1988-08-11 1995-03-08 テルモ株式会社 リポソームおよびその製法
IL91664A (en) 1988-09-28 1993-05-13 Yissum Res Dev Co Ammonium transmembrane gradient system for efficient loading of liposomes with amphipathic drugs and their controlled release
US5013556A (en) 1989-10-20 1991-05-07 Liposome Technology, Inc. Liposomes with enhanced circulation time
US5538954A (en) 1994-06-24 1996-07-23 A/S Dumex (Dumex Ltd.) Salts of tetracyclines
US5783568A (en) 1994-06-10 1998-07-21 Sugen, Inc. Methods for treating cancer and other cell proliferative diseases
US5543152A (en) 1994-06-20 1996-08-06 Inex Pharmaceuticals Corporation Sphingosomes for enhanced drug delivery
US6214388B1 (en) 1994-11-09 2001-04-10 The Regents Of The University Of California Immunoliposomes that optimize internalization into target cells
US5800833A (en) 1995-02-27 1998-09-01 University Of British Columbia Method for loading lipid vesicles
DE19605024A1 (de) 1996-01-31 1997-08-07 Schering Ag Neue selektive Taxane, Verfahren zu ihrer Herstellung und ihre pharmazeutische Verwendung
US5997899A (en) 1996-10-01 1999-12-07 Skyepharma Inc. Method for producing liposomes with increased percent of compound encapsulated
AU4990397A (en) 1996-10-22 1998-05-15 Dmitri Kirpotin Compound-loaded liposomes and methods for their preparation
US6210707B1 (en) 1996-11-12 2001-04-03 The Regents Of The University Of California Methods of forming protein-linked lipidic microparticles, and compositions thereof
US6787132B1 (en) 1997-12-04 2004-09-07 Yissum Research Development Company Of The Hebrew University Of Jerusalem Combined chemo-immunotherapy with liposomal drugs and cytokines
US7244826B1 (en) 1998-04-24 2007-07-17 The Regents Of The University Of California Internalizing ERB2 antibodies
US6726925B1 (en) 1998-06-18 2004-04-27 Duke University Temperature-sensitive liposomal formulation
US6355268B1 (en) 1998-09-16 2002-03-12 Alza Corporation Liposome-entrapped topoisomerase inhibitors
US7311924B2 (en) 1999-04-01 2007-12-25 Hana Biosciences, Inc. Compositions and methods for treating cancer
WO2000066125A1 (en) 1999-04-29 2000-11-09 Aventis Pharma S.A. Method for treating cancer using camptothecin derivatives and 5-fluorouracil
US6720001B2 (en) 1999-10-18 2004-04-13 Lipocine, Inc. Emulsion compositions for polyfunctional active ingredients
US6511676B1 (en) 1999-11-05 2003-01-28 Teni Boulikas Therapy for human cancers using cisplatin and other drugs or genes encapsulated into liposomes
US7025988B2 (en) 2000-02-04 2006-04-11 Lipoxen Technologies Limited Liposomes
US6545010B2 (en) 2000-03-17 2003-04-08 Aventis Pharma S.A. Composition comprising camptothecin or a camptothecin derivative and a platin derivative for the treatment of cancer
AU2001261473B2 (en) 2000-05-15 2006-09-14 Board Of Trustees Of The University Of Arkansas Compositions and methods for the treatment of colorectal cancer
MXPA02012817A (es) 2000-06-30 2004-07-30 Inex Pharmaceuticals Inc Drogas antineoplasicas liposomales y uso de las mismas.
TWI283575B (en) 2000-10-31 2007-07-11 Eisai Co Ltd Medicinal compositions for concomitant use as anticancer agent
AU2002305094B2 (en) 2001-03-26 2007-01-11 Alza Corporation Liposome composition for improved intracellular delivery of a therapeutic agent
US7219016B2 (en) 2001-04-20 2007-05-15 Yale University Systems and methods for automated analysis of cells and tissues
WO2003030864A1 (en) 2001-05-29 2003-04-17 Neopharm, Inc. Liposomal formulation of irinotecan
JP2005505526A (ja) 2001-07-23 2005-02-24 エピダウロス・バイオテクノロジー・アクチェンゲゼルシャフト Ｕｇｔ１ａ１に基づいたがんの改善治療の手段及び方法
US7850990B2 (en) 2001-10-03 2010-12-14 Celator Pharmaceuticals, Inc. Compositions for delivery of drug combinations
CA2752143C (en) 2002-05-15 2014-09-23 Sutter West Bay Hospitals Delivery of nucleic acid-like compounds
ATE458751T1 (de) 2002-05-31 2010-03-15 Transmolecular Inc Kombinationschemotherapie mit chlorotoxin
AU2003296897A1 (en) 2002-08-20 2004-05-04 Neopharm, Inc. Pharmaceutical formulations of camptothecine derivatives
US20050186208A1 (en) 2003-05-30 2005-08-25 Genentech, Inc. Treatment with anti-VEGF antibodies
EP4218730B1 (en) 2004-05-03 2023-11-01 Ipsen Biopharm Ltd. Liposomes useful for drug delivery
US8658203B2 (en) 2004-05-03 2014-02-25 Merrimack Pharmaceuticals, Inc. Liposomes useful for drug delivery to the brain
US7846473B2 (en) * 2004-06-01 2010-12-07 Terumo Kabushiki Kaisha Irinotecan preparation
JP2006248978A (ja) 2005-03-10 2006-09-21 Mebiopharm Co Ltd 新規なリポソーム製剤
TWI375673B (en) 2005-04-11 2012-11-01 Abbott Lab 1h-benzimidazole-4-carboxamides substituted with a quaternary carbon at the 2-position are potent parp inhibitors
AU2006306108B2 (en) 2005-10-25 2012-10-04 Celator Pharmaceuticals, Inc. Fixed ratio drug combination treatments for solid tumors
US20090148506A1 (en) 2005-12-22 2009-06-11 Awa Dicko Liposomal formulations comprising secondary and tertiary amines and methods for preparing thereof
DK2338487T3 (da) 2006-01-17 2013-12-09 Abbvie Bahamas Ltd Kombinationsterapi med PARP-inhibitorer
CN101442998B (zh) 2006-03-16 2012-03-14 比奥纽默里克药物公司 抗癌活性加强化合物和制剂及其用法
KR101598229B1 (ko) 2007-02-16 2016-02-26 메리맥 파마슈티컬즈, 인크. Ｅｒｂｂ3에 대한 항체 및 이의 용도
US20120003160A1 (en) 2007-06-29 2012-01-05 Amag Pharmaceuticals, Inc. Macrophage-Enhanced MRI (MEMRI) in a Single Imaging Session
ES2550759T3 (es) 2007-08-17 2015-11-12 Celator Pharmaceuticals, Inc. Formulaciones farmacológicas de platino mejoradas
US20100239652A1 (en) 2007-09-28 2010-09-23 Universitatsspital Basel Immunoliposomes for treatment of cancer
CA2705417A1 (en) 2007-11-12 2009-05-22 Bipar Sciences, Inc. Treatment of uterine cancer and ovarian cancer with a parp inhibitor alone or in combination with anti-tumor agents
EP2224804A4 (en) 2007-12-07 2011-06-01 Bipar Sciences Inc TREATMENT OF CANCER WITH COMBINATIONS OF TOPOÎSOMERASE INHIBITORS AND PARP INHIBITORS
EP2259797A2 (en) 2008-03-25 2010-12-15 Schering Corporation Methods for treating or preventing colorectal cancer
US8067432B2 (en) 2008-03-31 2011-11-29 University Of Kentucky Research Foundation Liposomal, ring-opened camptothecins with prolonged, site-specific delivery of active drug to solid tumors
EP2860260A1 (en) 2008-04-11 2015-04-15 Merrimack Pharmaceuticals, Inc. Human serum albumin linkers and conjugates thereof
US8852630B2 (en) 2008-05-13 2014-10-07 Yale University Chimeric small molecules for the recruitment of antibodies to cancer cells
KR20110112301A (ko) 2008-11-18 2011-10-12 메리맥 파마슈티컬즈, 인크. 인간 혈청 알부민 링커 및 그 콘쥬게이트
EP2424516A4 (en) 2009-05-01 2014-04-02 Oncozyme Pharma Inc PENTAMIDINE COMBINATIONS FOR THE TREATMENT OF CANCER
KR20120089754A (ko) 2009-12-03 2012-08-13 샹하이 헨그루이 파마수티컬 컴퍼니 리미티드 이리노테칸 또는 그의 하이드로클로라이드의 리포좀 및 그의 제조 방법
EP2575804A4 (en) 2010-06-04 2013-10-23 Abraxis Bioscience Llc METHOD FOR THE TREATMENT OF PANCREASCRE
JP2013531068A (ja) 2010-07-19 2013-08-01 バイパー サイエンシズ，インコーポレイティド ４−ヨード−３−ニトロベンズアミドを抗腫瘍剤と組み合わせて用いる乳癌の治療方法
MX349662B (es) 2010-07-22 2017-08-08 Univ California Anticuerpos de antigenos antitumorales y metodos de uso.
RU2541100C2 (ru) 2010-09-03 2015-02-10 Боард Оф Регентс Оф Зе Юниверсити Оф Небраска Способ и композиция для лечения рака
JP6208582B2 (ja) 2010-12-06 2017-10-04 メリマック ファーマシューティカルズ インコーポレーティッド アントラサイクリン系化学療法剤を含有しているｅｒｂｂ２標的免疫リポソームによる治療における心臓毒性を抑制するための用量及び投与
WO2012079582A1 (en) 2010-12-14 2012-06-21 Technical University Of Denmark Entrapment of radionuclides in nanoparticle compositions
AU2012217685B2 (en) 2011-02-15 2017-05-18 Merrimack Pharmaceuticals, Inc. Compositions and methods for delivering nucleic acid to a cell
HRP20170713T1 (hr) 2011-04-19 2017-07-14 Merrimack Pharmaceuticals, Inc. Bispecifično anti-igf-1r i anti-erbb3 antitijelo
JO3283B1 (ar) 2011-04-26 2018-09-16 Sanofi Sa تركيب يتضمن أفليبيرسيبت, حمض فولينيك, 5- فلورويوراسيل (5- Fu) وإرينوسيتان (FOLFIRI)
US8691231B2 (en) 2011-06-03 2014-04-08 Merrimack Pharmaceuticals, Inc. Methods of treatment of tumors expressing predominantly high affinity EGFR ligands or tumors expressing predominantly low affinity EGFR ligands with monoclonal and oligoclonal anti-EGFR antibodies
AU2013201584A1 (en) * 2012-03-12 2013-09-26 Merrimack Pharmaceuticals, Inc. Methods for treating pancreatic cancer using combination therapies comprising an anti-ErbB3 antibody
KR20150050524A (ko) 2012-04-17 2015-05-08 메리맥 파마슈티컬즈, 인크. 비침습적 이미징을 위한 조성물 및 방법
US9717724B2 (en) 2012-06-13 2017-08-01 Ipsen Biopharm Ltd. Methods for treating pancreatic cancer using combination therapies
WO2014113167A1 (en) 2012-12-14 2014-07-24 Merrimack Pharmaceuticals, Inc. Non-invasive imaging methods for patient selection for treatment with nanoparticulate therapeutic agents
HUE041687T2 (hu) 2013-03-27 2019-05-28 Taiho Pharmaceutical Co Ltd Antitumor szer, amely tartalmaz kis dózisú irinotekan-hidroklorid-hidrát-ot
EP3038600B1 (en) 2013-08-27 2020-06-03 Northeastern University Nanoparticle drug delivery system and method of treating cancer and neurotrauma
WO2015061592A1 (en) 2013-10-23 2015-04-30 Merrimack Pharmaceuticals, Inc. Liposomes for non-invasive imaging and drug delivery
WO2016094402A1 (en) 2014-12-09 2016-06-16 Merrimack Pharmaceuticals, Inc. Treatment of breast cancer with liposomal irinotecan
TW201701880A (zh) 2015-04-14 2017-01-16 莫瑞麥克製藥公司 改善持續釋放藥物治療之藥物動力學及治療指數之方法
SG10201913073YA (en) 2015-08-20 2020-03-30 Ipsen Biopharm Ltd Combination therapy using liposomal irinotecan and a parp inhibitor for cancer treatment
US20170049775A1 (en) 2015-08-21 2017-02-23 Merrimack Pharmaceuticals, Inc. Methods for Treating Metastatic Pancreatic Cancer Using Combination Therapies Comprising Liposomal Irinotecan and Oxaliplatin
CN114099437A (zh) 2015-10-16 2022-03-01 易普森生物制药有限公司 稳定喜树碱药物组合物
US20170202840A1 (en) 2016-01-14 2017-07-20 Merrimack Pharmaceuticals, Inc. Treatment of pancreatic cancer with liposomal irinotecan
WO2017172678A1 (en) 2016-03-30 2017-10-05 Merrimack Pharmaceuticals, Inc. Methods for treating cancer using combination therapies comprising an oligoclonal anti-egfr antibody preparation and lipsomal irinotecan
CN109640995A (zh) 2016-05-18 2019-04-16 易普森生物制药有限公司 用脂质体伊立替康治疗小细胞肺癌
US20170333421A1 (en) 2016-05-18 2017-11-23 Ipsen Biopharm Ltd. Population Pharmacokinetics of Liposomal Irinotecan
RU2761953C2 (ru) 2016-11-02 2021-12-14 Ипсен Биофарм Лтд. Лечение рака желудка с применением комбинационных видов терапии, содержащих липосомальный иринотекан, оксалиплатин, 5-фторурацил (и лейковорин)

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2015523355A (ja) * 2012-06-13 2015-08-13 メリマック ファーマシューティカルズ インコーポレーティッド リポソームイリノテカンを含む併用療法を用いた、膵臓癌を治療するための方法

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
ANNALS OF ONCOLOGY, vol. 18, JPN6021035248, 2007, pages 88 - 92, ISSN: 0004901993 *
ANNALS OF ONCOLOGY, vol. 24, JPN6021035247, 2013, pages 1567 - 1573, ISSN: 0004901994 *
CANCER CHEMOTHERAPY AND PHARMACOLOGY, vol. 67, JPN6021035246, 2010, pages 41 - 48, ISSN: 0004589054 *
STEFAN PEINERT: "SAFETY AND EFFICACY OF WEEKLY 5-FLUOROURACIL/ FOLINIC ACID/OXALIPLATIN/IRINOTECAN IN 以下備考", THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY, vol. VOL:2, NR:3, JPN5020000949, May 2010 (2010-05-01), GB, pages 161 - 174, ISSN: 0004589055 *

Also Published As

Publication number Publication date
IL266187A (en) 2019-06-30
AU2017354903B2 (en) 2023-04-13
CN110402163A (zh) 2019-11-01
SG10201912338RA (en) 2020-02-27
IL291679A (en) 2022-05-01
RU2019114952A (ru) 2020-12-03
TW201825097A (zh) 2018-07-16
SG11201903615WA (en) 2019-05-30
PH12019500892A1 (en) 2019-06-17
RU2019114952A3 (cg-RX-API-DMAC7.html) 2021-03-03
AU2017354903A1 (en) 2019-05-02
KR20190077441A (ko) 2019-07-03
MX392408B (es) 2025-03-24
EP3535026A1 (en) 2019-09-11
JP2022171808A (ja) 2022-11-11
EA201990979A1 (ru) 2019-09-30
US20200030302A1 (en) 2020-01-30
CA3040395A1 (en) 2018-05-11
MA46709A (fr) 2019-09-11
MY202377A (en) 2024-04-24
TWI791467B (zh) 2023-02-11
US11071726B2 (en) 2021-07-27
RU2761953C2 (ru) 2021-12-14
MX2019004783A (es) 2019-08-12
WO2018083470A1 (en) 2018-05-11
BR112019007844A2 (pt) 2019-07-16

Similar Documents

Publication Publication Date Title
JP2019533684A (ja) リポソームイリノテカン、オキサリプラチン、５−フルオロウラシル（およびロイコボリン）を含む併用療法を用いる胃がんの処置
JP7463329B2 (ja) リポソーム型イリノテカン及びオキサリプラチンを含む組み合わせ療法を使用して転移性膵臓癌を治療するための方法
JP6857210B2 (ja) リポソームイリノテカンを含む併用療法を用いた、膵臓癌を治療するための方法
HK40009222A (en) Treating gastric cancer using combination therapies comprising liposomal irinotecan, oxaliplatin, 5-fluoruracil (and leucovorin)
CA2993451C (en) Methods for treating metastatic pancreatic cancer using combination therapies comprising liposomal irinotecan and oxaliplatin
HK1257250B (en) Drug combination comprising liposomal irinotecan, oxaliplatin, 5-fluorouracil and leucovorin for treating metastatic pancreatic cancer

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20201029

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20201029

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20210831

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20210907

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20211206

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220106

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20220517

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220915

C60 Trial request (containing other claim documents, opposition documents)

Free format text: JAPANESE INTERMEDIATE CODE: C60

Effective date: 20220915

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20220926

C21 Notice of transfer of a case for reconsideration by examiners before appeal proceedings

Free format text: JAPANESE INTERMEDIATE CODE: C21

Effective date: 20220927

A912 Re-examination (zenchi) completed and case transferred to appeal board

Free format text: JAPANESE INTERMEDIATE CODE: A912

Effective date: 20221028

C211 Notice of termination of reconsideration by examiners before appeal proceedings

Free format text: JAPANESE INTERMEDIATE CODE: C211

Effective date: 20221101

A045 Written measure of dismissal of application [lapsed due to lack of payment]

Free format text: JAPANESE INTERMEDIATE CODE: A045

Effective date: 20240726